ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

teva gmbh - dimethylfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimethylfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 en 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastische middelen - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - ডাচ - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicine hydrochloride - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastische middelen - caelyx gepegyleerd liposomaal is aangegeven:als monotherapie bij patiënten met gemetastaseerde borstkanker, waar sprake is van een verhoogde cardiale risico ' s;voor de behandeling van gevorderde eierstokkanker bij vrouwen die niet in een eerste-lijn op platina gebaseerde chemotherapie regime;in combinatie met bortezomib voor de behandeling van progressieve multiple myeloom bij patiënten die ten minste één eerdere therapie en die al hebben ondergaan, of zijn niet geschikt voor beenmergtransplantatie;voor de behandeling van aids-gerelateerde kaposi sarcoom (ks) bij patiënten met lage cd4-tellingen (.

নেদারল্যান্ডস - ডাচ - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bayer animal health gmbh - toltrazuril - suspensie voor oraal gebruik - toltrazuril 50 mg/ml, - toltrazuril - biggen; kalveren; lammeren

নেদারল্যান্ডস - ডাচ - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dopharma research b.v. - ascorbinezuur (l-) (e 300); biotine; cholecalciferol; cyanocobalamine; dexpanthenol; foliumzuur; menadion; myo-inositol; nicotinamide; pyridoxinehydrochloride; retinolpropionaat; riboflavine natriumfosfaat 0-water; thiaminehydrochloride; tocoferol, dl-alfa acetaat - oplossing voor gebruik in drinkwater - ascorbinezuur (l-) (e 300) 20 mg/ml; biotine 10 µg/ml; cholecalciferol 5000 ie/ml; cyanocobalamine 20 µg/ml; dexpanthenol 6,5 mg/ml; foliumzuur 50 µg/ml; menadion 3 mg/ml; myo-inositol 1 mg/ml; nicotinamide 20 mg/ml; pyridoxinehydrochloride 2 mg/ml; retinolpropionaat 20000 ie/ml; riboflavine natriumfosfaat 0-water 1,25 mg/ml; thiaminehydrochloride 1 mg/ml; tocoferol, dl-alfa acetaat 30 mg/ml, - multivitamines, plain - kalveren; pluimvee; varkens

নেদারল্যান্ডস - ডাচ - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

pfizer b.v. rivium westlaan 142 2909 ld capelle a/d ijssel - esketaminehydrochloride 28,83 mg/ml samenstelling overeenkomend met ; esketamine 25 mg/ml - oplossing voor injectie - benzethoniumchloride ; natriumchloride ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507), - esketamine